AR122863A1 - Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos - Google Patents

Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos

Info

Publication number
AR122863A1
AR122863A1 ARP210101857A ARP210101857A AR122863A1 AR 122863 A1 AR122863 A1 AR 122863A1 AR P210101857 A ARP210101857 A AR P210101857A AR P210101857 A ARP210101857 A AR P210101857A AR 122863 A1 AR122863 A1 AR 122863A1
Authority
AR
Argentina
Prior art keywords
polypeptides
modified
including modified
agonize
wild
Prior art date
Application number
ARP210101857A
Other languages
English (en)
Spanish (es)
Inventor
John C Timmer
Florian Sulzmaier
Katelyn M Willis
Bryan Becklund
Brendan P Eckelman
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of AR122863A1 publication Critical patent/AR122863A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
ARP210101857A 2020-07-02 2021-07-01 Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos AR122863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063047681P 2020-07-02 2020-07-02

Publications (1)

Publication Number Publication Date
AR122863A1 true AR122863A1 (es) 2022-10-12

Family

ID=77127075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101857A AR122863A1 (es) 2020-07-02 2021-07-01 Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos

Country Status (12)

Country Link
US (1) US20230235005A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175979A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023532904A (cg-RX-API-DMAC7.html)
KR (1) KR20230035076A (cg-RX-API-DMAC7.html)
CN (1) CN116615440A (cg-RX-API-DMAC7.html)
AR (1) AR122863A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021299552A1 (cg-RX-API-DMAC7.html)
CA (1) CA3184618A1 (cg-RX-API-DMAC7.html)
IL (1) IL299542A (cg-RX-API-DMAC7.html)
MX (1) MX2022016532A (cg-RX-API-DMAC7.html)
TW (1) TW202216745A (cg-RX-API-DMAC7.html)
WO (1) WO2022006380A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
EP4477673A4 (en) * 2022-02-11 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co Ltd IMMUNOCONJUGATE AND ITS USE
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR20250143339A (ko) * 2023-02-06 2025-10-01 메르크 파텐트 게엠베하 VHH-기반 NKp46 결합제
EP4770754A1 (en) 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
SG11202005873QA (en) * 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Also Published As

Publication number Publication date
KR20230035076A (ko) 2023-03-10
JP2023532904A (ja) 2023-08-01
CN116615440A (zh) 2023-08-18
IL299542A (en) 2023-02-01
MX2022016532A (es) 2023-04-12
US20230235005A1 (en) 2023-07-27
CA3184618A1 (en) 2022-01-06
EP4175979A2 (en) 2023-05-10
WO2022006380A2 (en) 2022-01-06
JP2026094308A (ja) 2026-06-09
WO2022006380A3 (en) 2022-02-24
AU2021299552A1 (en) 2023-02-02
TW202216745A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
CL2021001779A1 (es) Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
CO2019009354A2 (es) Immunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
CL2021003457A1 (es) Proteínas de fusión flt3l-fc y métodos de uso
AR114445A1 (es) Conjugados de il-15, y sus usos
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
AR115024A1 (es) PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
AR112048A1 (es) Anticuerpos cd47 y métodos de uso de los mismos
UY37456A (es) Inmunoglobulinas y sus usos
MX2019011869A (es) Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
MX2022012541A (es) Inmunoconjugados.
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CO2024004910A2 (es) Proteína mutante de interleucina-2 y fusión de la misma
CL2015002686A1 (es) Muteínas de interleucina-2 para la expansion de células t reguladoras
MX394735B (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
UY35397A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
MX2022016532A (es) Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
CL2023001269A1 (es) Construcción polipeptídica que se une a cd3; composiciòn farmacéutica; y su uso.